Half-year report · HY
2269.TEDINET S100X368
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥574.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥1.15T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥569.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥40.9bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥44.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥41.6bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥82.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥43.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥39.9bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥44.3bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥21.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥50.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥26.9bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥24.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥29.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.23T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.18T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.18T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥440.0bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥392.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥793.9bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥791.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥774.6bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥69.9bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥78.2bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥56.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥66.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥73.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥102.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥9.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥69.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥38.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥40.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥37.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥61.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥17.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥79.27 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥186.08 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.66 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 60.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.2% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥506m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥506m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥2.4bn |
| Foodreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥458.4bn |
| Foodreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥457.9bn |
| Foodreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥495m |
| Foodreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥29.0bn |
| Pharmaceutica002reportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥117.0bn |
| Pharmaceutica002reportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥117.0bn |
| Pharmaceutica002reportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥10m |
| Pharmaceutica002reportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥14.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥575.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥574.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥506m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥43.3bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥318m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥318m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| Foodreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥455.4bn |
| Foodreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥455.1bn |
| Foodreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥307m |
| Foodreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥27.6bn |
| Pharmaceutica002reportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥113.9bn |
| Pharmaceutica002reportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥113.9bn |
| Pharmaceutica002reportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥10m |
| Pharmaceutica002reportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥18.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥569.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥569.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥318m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥46.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Subsidies received inv cf | InterimDuration | 91000000 | JPY |
| Purchase of investment securities inv cf | Prior1InterimDuration | -102000000 | JPY |
| Purchase of investment securities inv cf | InterimDuration | -352000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1InterimDuration | 20641000000 | JPY |
| Proceeds from sales of investment securities inv cf | InterimDuration | 392000000 | JPY |
| Other net inv cf | Prior1InterimDuration | -1333000000 | JPY |
| Other net inv cf | InterimDuration | -1510000000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -12188000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -38937000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1InterimDuration | 19997000000 | JPY |
| Net increase decrease in short term loans payable fin cf | InterimDuration | 7965000000 | JPY |
| Increase decrease in commercial papers fin cf | Prior1InterimDuration | 10000000000 | JPY |
| Increase decrease in commercial papers fin cf | InterimDuration | 26000000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | － | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | 20000000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -2115000000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -1312000000 | JPY |
| Decrease increase in treasury stock fin cf | Prior1InterimDuration | -30043000000 | JPY |
| Decrease increase in treasury stock fin cf | InterimDuration | -5000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -13229000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -13507000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1InterimDuration | -801000000 | JPY |
| Dividends paid to non controlling interests fin cf | InterimDuration | -766000000 | JPY |
| Other net fin cf | Prior1InterimDuration | -1212000000 | JPY |
| Other net fin cf | InterimDuration | -766000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -17404000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | 37606000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -1013000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 458000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -26845000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -10333000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 102832000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 66398000000 | JPY |
| Increase decrease in cash and cash equivalents resulting from change in accounting period of consolidated subsidiaries cce | Prior1InterimDuration | -2609000000 | JPY |
| Increase decrease in cash and cash equivalents resulting from change in accounting period of consolidated subsidiaries cce | InterimDuration | － | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1InterimDuration | － | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | InterimDuration | 391000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 73377000000 | JPY |
| Cash and cash equivalents | InterimInstant | 56456000000 | JPY |
| Promotion expenses sga | Prior1InterimDuration | 10882000000 | JPY |
| Promotion expenses sga | InterimDuration | 10767000000 | JPY |
| Personal expenses sga | Prior1InterimDuration | 34679000000 | JPY |
| Personal expenses sga | InterimDuration | 35854000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 6465000000 | JPY |
| Provision for bonuses sga | InterimDuration | 6850000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 2024000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 1532000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E21902-000FoodReportableSegmentsMember | 455126000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E21902-000Pharmaceutica002ReportableSegmentsMember | 113879000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 569006000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |